MK-3214

MK-3214 is an investigational Merck small-molecule pharmaceutical candidate in early clinical development for **hypercholesterolaemia**. Publicly available evidence confirms a first-in-human Phase 1 study in healthy volunteers sponsored by Merck Sharp & Dohme, but the exact international nonproprietary name, detailed chemical identity, and validated molecular target have not been publicly disclosed in the sources reviewed. Based on Merck's therapeutic positioning and external regulatory listings, MK-3214 appears to be a cardiovascular/lipid-lowering drug candidate under evaluation for lowering atherogenic cholesterol, but its precise mechanism of action remains undisclosed.